Search

Displaying results 441 - 450 of 4650 in total
  1. Drug

    Axicabtagene ciloleucel

    go.drugbank.com/drugs/DB13915
    ApprovedInvestigational

    [A216163] Axicabtagene ciloleucel was approved by the FDA on October 18th, 2017. … [L40054] Axicabtagene ciloleucel was later approved by the EMA on August 23, 2018.[L42090]

  2. Drug

    Metamizole

    go.drugbank.com/drugs/DB04817
    ApprovedInvestigationalWithdrawn

    [L42975] In 1963, metamizole was withdrawn from the Canadian market and banned in the UK, France, Sweden, Norway and Australia. … [A251885] Metamizole was formerly marketed in the US as Dimethone tablets and injection, Protemp oral liquid, and other drug products, and was withdrawn due to its association with potentially fatal agranulocytosis

  3. Drug

    Delandistrogene moxeparvovec

    go.drugbank.com/drugs/DB16802
    ApprovedInvestigational

    Microdystrophin is a truncated, functional form of dystrophin. … Delandistrogene moxeparvovec is an adeno-associated virus vector-based gene therapy developed by Sarepta Therapeutics.

  4. Drug

    Febuxostat

    go.drugbank.com/drugs/DB04854
    ApprovedInvestigational

    [L32238] Gout is a form of arthritis that is caused by the accumulation of uric acid crystal in or around a joint, leading to inflammation and further deposition of uric acid crystal deposition in bones … [A39743] In early 2008, febuxostat was granted marketing authorization by the European Commission for the treatment of chronic hyperuricemia and gout.

  5. Drug

    Donanemab

    go.drugbank.com/drugs/DB16647
    ApprovedInvestigational

    [A232214] On July 2, 2024, donanemab was approved by the FDA for the treatment of AD in patients with mild cognitive impairment or dementia symptoms.

  6. Drug

    Mavacamten

    go.drugbank.com/drugs/DB14921
    ApprovedInvestigational

    [A248440] Mavacamten was also approved by Health Canada in October 2022 and by EMA in July 2023 for the same indication.[L44106,L47471] … It received initial US FDA approval in 2022, and it is one of the first myosin inhibitors to be used in humans.

  7. Drug

    Atosiban

    go.drugbank.com/drugs/DB09059
    ApprovedInvestigational

    Although initial studies suggested it could be used as a nasal spray and hence would not require hospital admission, it is not used in that form. … Atobisan was developed by the Swedish company Ferring Pharmaceuticals. It was first reported in the literature in 1985.

  8. Drug

    Sodium carbonate

    go.drugbank.com/drugs/DB09460
    ApprovedWithdrawn

    Sodium Carbonate is the disodium salt of carbonic acid with alkalinizing property. When dissolved in water, sodium carbonate forms carbonic acid and sodium hydroxide. As a strong base, sodium hydroxide neutralizes gastric acid thereby ac...

  9. Drug

    Levopropoxyphene

    go.drugbank.com/drugs/DB06793
    ApprovedWithdrawn

    Levopropoxyphene is a stereoisomer of propoxyphene in the form of 2S, 3R enantiomer. It was sold as an antitussive, but it was removed from the market in the 70s. … [T133] Levopropoxyphene was developed by Lilly and FDA approved on March 21st, 1962. This drug presented different dosages and it was administered as a capsule or suspension.

  10. Drug

    Omega-3-carboxylic acids

    go.drugbank.com/drugs/DB09568
    ApprovedWithdrawn

    The increased bioavailability is explained because OM3-CA is found in a form of polyunsaturated free fatty acids as opposed to other products whose form is as ethyl esters. … [A25808] It was developed by AstraZeneca Pharmaceuticals and firstly approved by the FDA on May 05, 2014.[L2386]